You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股暗盤丨“A+H”又添猛將!恒瑞醫藥(1276.HK)暗盤大升近30%
恒瑞醫藥(1276.HK)在富途行情的暗盤段高開高走,一度大升28.26%至56.5港元,市值突破3700億港元。該股將於5月23日(明日)在香港聯交所上市交易,每手買賣單位為200股H股。恒瑞醫藥的IPO定價為44.05港元/股,為發行價區間的最高端。此次共計發行2.245億股,募集約99億港元(13億美元)的資金,成為近五年港股醫藥板塊最大IPO。恒瑞醫藥創立於1970年,是國內最具創新能力的製藥龍頭企業之一。自2000年在上交所上市以來,公司持續通過股票分紅等方式回報股東,目前累計實施完成的現金分紅總額約80.29億元,相當於公司當年A股上市募集資金的16.8倍。分析人士指出,本次港股上市不僅拓寬公司融資渠道,更推動資本市場對恒瑞的“價值再發現”。隨着上市時間點臨近,A股市場已率先作出積極反饋,恒瑞醫藥A股今年以來已累升超20%,遠遠跑贏大盤表現,同期滬指升幅不足1%。瑞銀證券全球投資銀行部聯席主管諶戈表示,“A+H”兩地上市的公司數量激增,是市場流動性改善以及政策環境優化協同帶來的成果。近期港股市場基石投資者的心態正在發生變化,機構對基石投資的興趣明顯增強,海外長線資金參與熱情高升。“寧德時代、恒瑞醫藥等企業均為細分領域領軍者,其高質量的運營狀況疊加AH股價差收窄,對全球長線資金具備較強的吸引力。”
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account